

TONSILS ARE MAJOR SITES OF PROLONGED SARS-COV-2 INFECTION IN CHILDREN

Thais M. Lima^{1*}, Ronaldo B. Martins^{1,2*}, Carolina S. Miura^{3*}, Maria V. O. Souza¹, Murilo H. A. Cassiano¹, Tamara S. Rodrigues¹, Flávio P. Veras², Josane F. Sousa¹, Rogério Gomes¹, Glaucia M. Almeida¹, Stella R. Melo¹, Gabriela C. Silva¹, Matheus Dias¹, Carlos F. Capato¹, Maria L. Silva¹, Veridiana E. D. Barros¹, Lucas R. Carenzi³, Dario S. Zamboni¹, Daniel M. M. Jorge¹, Edwin Tamashiro³, Wilma T. Anselmo-Lima³, Fabiana C. P. Valera^{3&}, Eurico Arruda^{1&***}.

1. Department of Cell Biology and Virology Research Center, University of Sao Paulo School of Medicine, Ribeirão Preto, Brazil.
2. Department of Clinical Analyses, Toxicology and Food Science, University of Sao Paulo, School of Pharmaceutical Science of Ribeirão Preto, Brazil.
3. Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, University of Sao Paulo School of Medicine, Ribeirão Preto, Brazil.

&*These authors contributed equally to this work.

**Corresponding author: Eurico Arruda; Department of Cell Biology, University of São Paulo School of Medicine, Av. Bandeirantes 3900, Ribeirão Preto, SP, Brazil, 14049-900. Phone: 55-16-33153337. Email: eaneto@fmrp.usp.br.

Running title: Persistent SARS-CoV-2 lymphoid infection.

ABSTRACT

In the present study, we show that SARS-CoV-2 can infect palatine tonsils and adenoids in children without symptoms of COVID-19, with no history of recent upper airway infection. We studied 48 children undergoing tonsillectomy due to snoring/OSA or recurrent tonsillitis between October 2020 and September 2021. Briefly, nasal cytobrush (NC), nasal wash (NW) and tonsillar tissue fragments obtained at surgery were tested by RT-PCR, immunohistochemistry (IHC), flow cytometry and neutralization assay. We detected the presence of SARS-CoV-2 in at least one specimen tested in 25% of patients (20% in palatine tonsils and 16.27% in adenoids, 10.41% of NC and 6.25% of NW). Importantly, in 2 of the children there was evidence of laboratory-confirmed acute infection 2 and 5 months before surgery. IHC revealed the presence of SARS-CoV-2 nucleoprotein in epithelial surface and in lymphoid cells in both extrafollicular and follicular regions, in adenoids and palatine tonsils. Flow cytometry showed that CD20⁺ B lymphocytes were the most infected phenotypes by SARS-CoV-2 NP, followed by CD4⁺ and CD8⁺ T lymphocytes, and CD14⁺ macrophages and dendritic cells. Additionally, IF indicated that SARS-CoV-2-infected tonsillar tissues had increased expression of ACE2 and TMPRSS2. NGS sequencing demonstrated the presence of different SARS CoV-2 variants in tonsils from different tissues. SARS-CoV-2 antigen detection was not restricted to tonsils, but was also detected in nasal cells from the olfactory region. In conclusion, palatine tonsils and adenoids are sites of prolonged infection by SARS-CoV-2 in children, even without COVID-19 symptoms.

1. INTRODUCTION

SARS-CoV-2 causes COVID-19, a respiratory disease affecting people of all ages worldwide.¹ However, severe COVID-19 is much less frequent in children and adolescents than in adults.² The reasons for children having less severe disease are not entirely understood, but lower expressions of ACE2 and TMPRSS2 in children's respiratory tract are contributing factors.³

We have previously reported high rates of PCR detection of respiratory viruses, including endemic coronaviruses, in tonsils and adenoids from patients with chronic tonsillar diseases, without recent history of symptomatic airway infections.⁴ This finding was later confirmed by other groups,^{5,6,7} indicating that human tonsils are sites of asymptomatic respiratory virus infections. This prompted us to test whether SARS-CoV-2 was also detected in children's tonsils during the COVID-19 pandemic. Here we report detection of SARS-CoV-2 RNA and protein in tonsils, nasal cytobrushes, and respiratory secretions from children with tonsillar hypertrophy lacking symptoms of COVID-19, and determine the types of infected cells.

2. PATIENTS AND METHODS

2.1. *Study design and sample processing*

This cross-sectional study was done from October 2020 to September 2021, at the Otorhinolaryngology Division of the School of Medicine of Ribeirão Preto, University of São Paulo, and enrolled 3 to 11-year-old children who underwent adenoidectomy and/or tonsillectomy to treat recurrent tonsillitis or obstructive sleep apnea. The study was approved by the Ethics Committee of the Clinical Hospital, Ribeirão Preto Medical School, University of São Paulo. Exclusion criteria were symptoms of acute respiratory infections in the month before surgery, craniofacial malformations, genetic syndromes, deposit diseases, immunodeficiencies, and suspected tonsillar cancer. None of the children had been vaccinated, since COVID-19 vaccines had not been approved in Brazil at that time.

On the day of surgery parents/guardians who agreed to participate signed informed consents. A questionnaire was filled with data on previous exposure to COVID-19, demographics, comorbidities, indications for tonsillectomy, and relevant

physical examination findings, and recorded using REDCap software (Vanderbilt University, USA).

During surgery, the following samples were obtained: bilateral nasal wash (10 ml of saline solution instilled and immediately aspirated); bilateral cytobrush of the olfactory area under a 0° rigid optical view (a small brush was positioned close to the olfactory fossa, rotated ten times, and immediately placed into sterile RPMI medium with 4% antibiotic/antimycotic solution (Gibco, Grand Island, USA); 4 ml of peripheral blood for serology; adenoid and palatine tonsil tissues immediately placed in the same medium used for the cytobrushes. All samples were transported to the laboratory on ice within 2 hours.

The tissue specimens were washed in PBS to remove debris and blood clots, and used to prepare four aliquots for: qRT-PCR, virus isolation in cell culture, purification of tonsillar mononuclear cells (TMNC), and fixation for histological tests. Tissue pieces of $\sim 0.25 \text{ cm}^3$ were treated with collagenase type I (100 U/ml) and dispase (0.6 U/ml) for 1h at 37°C (Gibco, Grand Island, USA), then passed through a nylon mesh to obtain a cell suspension, which was used for: 1) mixing with 2X viral transport medium (VTM), consisting of minimum essential medium (MEM) with 20% FBS and 15% glycerol for viral isolation; 2) RNA extraction using Trizol; 3) backup in RNA-later (Invitrogen); 4) isolation of TMNCs by Ficoll-Paque™, which were suspended in freezing medium (RPMI with 20% FBS and 10% DMSO). Aliquots were stored at -80°C. Another piece of tonsillar tissue was placed in Carnoy's fixative for 12h and embedded in paraffin. The nasal washes and cytobrushes were used to prepare aliquots in VTM and Trizol, and the remainder was used to prepare cell pellets that were spotted onto glass slides, fixed with acetone and stored at -20°C for immunofluorescence.

2.2. Quantitation of SARS-CoV-2 RNA.

SARS-CoV-2 RNA was quantitated by real-time RT-PCR (qRT-PCR) with primers and probes for the N2 and E genes, according to protocols proposed by the USA Centers for Disease Control and Prevention, and the Charité Group (Table 1). The one-step reaction was assembled with 1000 ng of total RNA, specific primers (20 μM) and probe (5 μM), and the qPCR BIO Probe 1-Step Go-PCR Biosystems

(Applied Biosystems, Foster City, USA) with the parameters: 55°C for 10 min, 95°C for 2 min, 40 cycles of 95°C for 5 s, 60°C for 30 s, on a Step-One Plus (Applied Biosystems).

SARS-CoV-2 qRT-PCR was done in triplicate and results were normalized by amplification of the RNaseP gene. SARS-CoV-2 genome loads were extrapolated using a standard curve prepared with a plasmid containing a 944 bp amplicon of the N gene, inserted in the TA cloning vector (PTZ57R/T CloneJet™ Cloning Kit (Thermo Fisher®). Viral RNA loads were plotted with GraphPad® Prism 8.4.2 194 software.

2.3. Immunohistochemistry for SARS-CoV-2 antigen in adenotonsillar tissue.

SARS-CoV-2 antigen was detected *in situ* in tissue sections by immunohistochemistry (IHC). IHC standardization was done with Vero CCL-81 cells infected with parental SARS-CoV-2 Wuhan lineage as positive controls. Tissue sections (3µm) were deparaffinized, rehydrated and subjected to the previously published protocols.⁸ Red-purple signal was developed with AEC peroxidase system kit (SK-4800, Vector Laboratories, Burlingame, CA) and sections were counterstained with Harris hematoxylin (Vector) and scanned with a ScanScope VS120 (Olympus Life Sciences, Tokyo, Japan) in bright field, using 400x magnification.

2.4. Immunofluorescence for ACE2, TMPRSS2 and SARS-CoV-2 S protein in tonsils.

Tissue sections were deparaffinized in three xylene baths (Synth, Diadema, Brazil) for 5 minutes each, and hydrated by sequential incubations of 3 minutes each in decreasing ethanol concentrations (JTBacker) (100%, 90%, 80%, 70%, and 50%). Sections were blocked for 20 minutes in PBS with 0.01% BSA (Gibco) before antibody incubation. Slides were stained for 1 hour with the following primary antibodies diluted in PBS-BSA: rabbit monoclonal anti-SARS-CoV-2 S protein (Invitrogen) diluted 1:500; goat polyclonal anti-ACE2 (R&D systems) diluted 1:200; or mouse monoclonal anti-TMPRSS2 (Millipore) diluted 1:200. After washing with Tris-buffered saline with 0.1% Tween-20 (TBST), slides were incubated with AlexaFluor 488-labeled secondary alpaca anti-mouse

IgG antibodies (Jackson ImmunoResearch) diluted 1:1000, or alpaca anti-rabbit IgG AlexaFluor 594 (Jackson ImmunoResearch) diluted 1:1000. Nuclei were stained with DAPI (Vector) and images were acquired by Axio Observer combined with LSM 780 confocal microscope (Carl Zeiss) at 63x magnification at the same setup of zoomed and laser rate. Ten random fields per sample were analyzed at the x and y focal planes to measure the mean fluorescence intensity of ACE2 and TMPRSS2. Images were analyzed using Fiji by Image J.

2.5. Indirect immunofluorescence staining for SARS-CoV-2 N protein in nasal cytobrush samples.

Slides were defrosted and incubated with a permeabilizing/blocking solution of PBS with 0.01% Triton, 1% BSA (Sigma) and 5% goat serum for 5 min at room temperature. Slides were washed in PBS and incubated with primary rabbit polyclonal antibody anti-SARS-CoV-2 N protein (Creative Diagnostics) at 37°C for 1 hour. After blocking with SuperBlock™, slides were incubated with a Alexa 594-conjugated goat anti-rabbit secondary antibody (Abcam). The nuclei were stained with DAPI (Thermo Fisher), and images were obtained with a confocal fluorescence Leica TCS SP8 microscope (Leica Microsystems).

2.6. Flow cytometry of dissociated tonsillar lymphomononuclear cells

Frozen purified TMNCs were analyzed by flow cytometry after a 30 min staining at 4°C using antibodies for CD4 (PerCP-Cy5.5), CD8 (PE-Cy7), CD11c (PE-Cy7), CD14 (PerCP), CD20 (PE-Cy7) and CD123 (PerCP-Cy5.5) (BD Pharmingen). Cells were then washed, permeabilized and fixed with BD Cytotfix/Cytoperm™ kit. Intracellular SARS-CoV-2 was stained with rabbit anti-SARS-CoV-2 NP antibody for 1 h, followed by anti-rabbit IgG-APC secondary antibody (BD Pharmingen) for 30 min. TMNCs obtained from tonsils RT-PCR-negative for SARS-CoV-2 were used as negative controls. Cell preparations stained only with the IgG-APC secondary antibody were used for calibration of PE acquisition. Acquisition was performed in fixed cells in a flow cytometer (BD Accuri C6; BD Biosciences) and then analyzed using FlowJo software (Tree Star).

2.7. Serology assays.

COVID-19 IgM/IgG detections in patients sera were done using two rapid test kits from Nantong Egens Biotechnology and Genrui Biotech Inc, following the manufacturer's instructions. Determination of 100% virus neutralization titer (VNT₁₀₀) was done by the same protocol we previously published.⁹

2.8. Sequencing of SARS-CoV-2 genomes

SARS-CoV-2 genome sequencing followed the ARTIC nCoV-2019 protocol v3 (<https://protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>)¹⁰ with PCR cycling modifications previously proposed.¹¹ Briefly, reverse transcription was performed with the LunaScript RT SuperMix Kit (NEB), using total RNA from tonsillar tissues and cytobrushes that had yielded Ct values ≤ 38 for genes E and N by qRT-PCR. Two multiplexed PCR products (Pool A = 110 primers pairs and Pool B = 108 primers pairs) were generated using the Q5 Hot Start High-Fidelity DNA Polymerase (NEB) and the primer scheme from IDT ARTIC nCoV-2019 V3 Panel. PCR products were purified using Agencourt AMPure XP beads (Beckman Coulter™) and the DNA concentration was measured by the Qubit 2 Fluorometer using the Qubit dsDNA HS Assay Kit (Invitrogen). DNA products (Multiplex PCR pools A and B) were pooled together in a final concentration of 50 fmol. The Ligation Sequencing kit used in the MinION library preparation was the SQK-LSK-109 and Native Barcoding was done with the NANO-EXPND196 kit (Oxford Nanopore, Oxford, UK). The obtained library was loaded on R9.4 Oxford MinION flowcells (FLO-MIN106) and sequenced using the MinION Mk1B device.

2.10. Bioinformatic analysis and sequence availability.

The pipeline included (i) the ONT MinKNOW software for collection of raw data and quality control, and (ii) Guppy (v6.0.1) for high accuracy base calling. Assembly

of the high-accuracy base called Fastq files was done by the nCoV-2019 novel coronavirus bioinformatics protocol (<https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html> accessed on January 12, 2022) with Minimap2¹² and Rampart¹³ for genome coverage analysis.

The assembled genomes were analyzed with Nextclade v1.14.0 (<https://clades.nextstrain.org/> accessed on August 26, 2022)¹⁴ and Pangolin v4.0 (<https://github.com/cov-lineages/pangolin> accessed on January 20, 2022)¹⁵ to identify the clade and lineages.

Raw Minion Nanopore reads from experiment were submitted to the SRA NCBI database under the Bioproject ID PRJNA876260, and the following BioSample IDs: SAMN30649069, SAMN30649070, SAMN30649072, SAMN30649075, SAMN30649076, SAMN30649077, SAMN30649078, SAMN30649079, SAMN30649080, and SAMN30649081. Control raw Minion Nanopore reads were submitted to the SRA NCBI database under the Bioproject ID PRJNA909758, and the following BioSample IDs: SAMN32093249.

2.11. Statistical analysis

Continuous data was analyzed by Student t test or Mann–Whitney test, depending on normal distribution. Statistical tests and graph plotting were performed with GraphPad Prism 8.4.2 software.

3. RESULTS

3.1. Demographic characteristics

A total of 48 patients (caucasian: 57.2%) were enrolled in the study. The patients were aged 3 to 11 years (mean 5.9 ± 2.2); 30 were boys (62.5%), and 24 (50%) did not have associated diseases (Table 2). Among the reported comorbidities, allergic rhinitis was reported in 19 children (39.6%), recurrent otitis media in 6 (12.5%), and mild asthma in 4 (8.3%). According to the parents/guardians, the last acute upper airways infection requiring or not antibiotics occurred 1 to 24 (average 9.2) months before surgery. Eight children (17%) had been exposed to confirmed COVID-19 in the household forty days to six months

before surgery. Two patients had previous laboratory-confirmed SARS-CoV-2 infection: one had a positive IgM test three months before surgery, and the other had a positive RT-PCR in respiratory secretion five months before surgery. An additional child reported smell and taste changes that occurred more than one month prior surgery, but was not tested for SARS-CoV-2 (Supplementary Table 1).

3.2. Detection of SARS-CoV-2 RNA and antigen.

SARS-CoV-2 RNA was detected by RT-PCR in at least one sample from 12 of the 48 patients (25%). In the majority of them, more than one sample was positive (Table 3). The SARS-CoV-2 detection rates were 20% in palatine tonsils, 16% in adenoids, 10% in nasal cytobrushes, and 6% in nasal washes. SARS-CoV-2 viral loads varied widely from 186 to 7114 copies of genome equivalents per μg RNA considering tonsillar tissues, nasal washes and nasal cytobrushes (Figure 1A), and although the median viral load in tonsillar tissues was about two-fold higher than in nasal specimens, there was no significant difference among samples.

SARS-CoV-2-positive samples were detected in patients without previous history (personal or in household member) of exposure to SARS-CoV-2, whereas negative samples were found in patients who had been exposed to confirmed COVID-19 cases in the family one to five months before surgery. Five of 12 SARS-CoV-2-positive children had no comorbidities, and the most frequent comorbidity was allergic rhinitis (4 of 12) (Table 3).

Immunohistochemistry was done on all tissue sections from SARS-CoV-2-positive tonsils, and two thirds of them were positive for SARS-CoV-2 antigen, which was detected in tonsillar epithelia and also in scattered cells in the lymphoid compartment, including lymphoid follicles and extrafollicular areas, in both tonsil types (Figure 1B, 1C, and 1D).

3.2. Expression of ACE2 and TMPRSS2 in tonsils.

Immunofluorescence revealed that the expressions of the main SARS-CoV-2 receptor (ACE2) and S-cleaving transmembrane protease (TMPRSS2) in tonsillar tissue sections was significantly more intense in tissues positive for SARS-CoV-2 as compared to negative ones (Figure 2A). The same areas of enhanced expression were also positive for the SARS-CoV-2 spike protein. The mean differences in

fluorescence intensity between SARS-CoV-2-infected and non-infected patients was 4815 ± 840.8 for ACE2 and 9471 ± 847.5 for TMPRSS2 ($p < 0.0001$) (Figure 2B).

3.3. Cells infected by SARS-CoV-2 in tonsillar tissues

Gates analyses, in Figure 3A, from flow cytometry showed that CD20⁺ B lymphocytes were by far the most frequent cell type, averaging 24.21% and 24% of all SARS-CoV-2-infected TMNCs, respectively in palatine tonsils and adenoids. CD4⁺ T lymphocytes averaged 12.31% and 10.26% of SARS-CoV-2-positive cells, respectively in palatine tonsils and adenoids, and CD8⁺ T lymphocytes averaged 9.87% and 18.18% of SARS-CoV-2-positive cells, respectively in palatine tonsils and adenoids. Among antigen-presenting cells (APC), CD14⁺ macrophages represented 4.56% and 10.17% SARS-CoV-2-positive cells, respectively in palatine tonsils and adenoids, while CD123⁺ dendritic cells were the least abundant cell type, with averages of 2.18% and 4.03% of SARS-CoV-2-positive cells, respectively in palatine tonsils and adenoids. In summary, CD20⁺ B lymphocytes were the most frequent SARS-CoV-2-infected cell in both tonsillar tissue, followed by CD4⁺, CD8⁺, CD14⁺ and CD123⁺ in palatine tonsils, and by CD8⁺, CD4⁺, CD14⁺ and CD123⁺ in adenoids (Figure 3).

3.4. SARS-CoV-2 RNA and antigen detection in nasal cytobrushes.

Cytobrush samples from the olfactory region were positive for SARS-CoV-2 RNA in 5 of the 12 SARS-CoV-2-positive patients, all of whom were also positive in tonsillar tissues. Immunofluorescence revealed SARS-CoV-2-positive cells in cytobrushes from 2 of these 5 patients (Figure 4).

3.5. SARS-CoV-2 serology

Rapid tests for anti-SARS-CoV-2 IgM and IgG antibodies were done in 11 of the 12 SARS-CoV-2-positive patients, whose sera were available, and IgG was detected in 5 patients (45%), while no patient was IgM-positive. This indicates that at least 5 of the 12 SARS-CoV-2-positive patients were not in the acute phase of the infection. Sera from all 5 IgG-positive patients neutralized SARS-CoV-2 in vitro, yet in low titers, as determined by VNT₁₀₀ (Table 3).

3.6. SARS-CoV-2 genome sequences.

Nanopore sequencing done in 12 samples (9 tonsillar tissues and 3 cytobrushes) from 10 patients yielded SARS-CoV-2 genome sequences in eight children (10 samples). The total length of SARS-CoV-2 sequences varied from 346 to 27,615 nucleotides, with six of them covering less than 40% of the genome length at a 20X depth (Supplementary Table 2). The sequence analysis revealed several Pangolin lineages (Figure 5), all of which circulated in Brazil during the study period.¹⁶

4. DISCUSSION

This study showed that SARS-CoV-2 was detected in upper respiratory tract samples from one quarter of children undergoing tonsillectomy, even in the absence of recent history for COVID-19. This roughly five-fold higher rate than the approximately 5% reported for seasonal coronaviruses in similar cohorts,⁴⁻⁷ may result from the sheer intense circulation of SARS-CoV-2 in Brazil in 2021, or from an enhanced propensity of SARS-CoV-2 to infect tonsils, or both.

The time of the patient's initial exposure to SARS-CoV-2 could not be determined in this cohort, nor was it possible to define a past episode of acute infection for most of the SARS-CoV-2-positive children. Thus, these children can be regarded as asymptomatic SARS-CoV-2 carriers, in agreement with reports that children are more likely than adults to have mild or asymptomatic SARS-CoV-2 infections.^{17, 18} The lower severity of COVID-19 in children can be attributed, at least in part, to some degree of cross-protection afforded by memory T-cell responses to previous infections by endemic coronaviruses.¹⁹ Also, a more vigorous innate immune response to SARS-CoV-2 in children than in adults could more efficiently contain the agent at the portal of entry, curb the spread to other tissues and reduce illness severity.²⁰

SARS-CoV-2 RNA was detected by qRT-PCR in more than one sample from some of the virus-positive children, with viral loads varying from hundreds to thousands of copies per microgram of RNA, suggesting that they may have undergone tonsillectomy at different times post-infection. Nevertheless, the time of initial exposure to SARS-CoV-2 was unknown and most children had no clear symptomatic phase, which hampers the establishment of correlations between duration of infection and viral loads at the time of tonsillectomy. It is important to

stress that 5 of the 12 children were IgG-positive, but none was IgM-positive for SARS-CoV-2.

In addition to the detection of SARS-CoV-2 RNA, which could be regarded as some remnant from a past infection, the present study revealed structural viral protein *in situ* in adenoids and palatine tonsils, in both epithelial and lymphomononuclear cells of different lymphoid compartments. This information is novel and provides further evidence for the presence of viral protein synthesis, hence viral activity, in tonsils of children without overt COVID-19. Also, the presence of SARS-CoV-2 protein in cells from the olfactory region in two children who also had virus detected in tonsils, indicates that prolonged SARS-CoV-2 infection is not restricted to tonsillar cells.

SARS-CoV-2 antigen was detected by flow cytometry in the major types of TMNCs, including B and T lymphocytes, macrophages and dendritic cells. Remarkably, this agrees with our previous report that SARS-CoV-2 infects the same range of peripheral blood mononuclear cells (PBMC) from adult COVID-19 patients, inducing apoptosis of infected cells, thus contributing to lymphopenia.^{21, 22} Also, post-mortem studies revealed SARS-CoV-2 infection in human lymphomononuclear cells, with histological alterations in spleens, lymph nodes, and gut-associated lymphoid tissue.^{23, 24} Those findings, along with the present observations in asymptomatic children, suggest that SARS-CoV-2-infected lymphomononuclear cells may intermigrate among secondary lymphoid organs, where intense B lymphocyte maturation and T lymphocyte activation take place.

ACE2 and TMPRSS2 proteins are highly expressed in the upper respiratory tract,²⁵ and the present finding of even higher ACE2 and TMPRSS2 expressions in SARS-CoV-2-infected tonsils may suggest that SARS-CoV-2 tonsillar infection promotes increased expression of ACE2 and TMPRSS2. Alternatively, a higher constitutive expression of ACE2 and TMPRSS2, depending on individual variation, could predispose some children to SARS-CoV-2 infection in tonsils.

B lymphocytes comprised roughly one quarter of SARS-CoV-2-infected TMNCs in both types of tonsils, which is not surprising, considering that they are the most abundant cells in secondary lymphoid organs. Of note, B lymphocytes were also the most frequently infected cells in PBMCs from acute COVID-19 adult patients.²¹

The median frequencies of CD8+T lymphocytes in SARS-CoV-2-infected TMNCs were respectively 10% and 18% in palatine tonsils and adenoids, consistent with the rates found in PBMCs from acute COVID-19 patients.²¹ The infection of CD8+T lymphocytes by viruses is surprising, considering that these are the very cells that perform cytotoxicity of virus-infected cells, and thus are central in the combat of viral infections. We have previously reported silent infection of tonsillar CD8+T lymphocytes also by influenza A virus,²⁶ suggesting that infection of these cells by viruses may have been previously overlooked. It has been suggested that SARS-CoV-2 persistence may be associated with a virus-specific CD8+T cell response,²⁷ which was not assessed in the present study.

SARS-CoV-2 was also detected in tonsillar CD14⁺ monocytes and CD123⁺ dendritic cells, which play important roles as components of the innate immune response. It is presently unknown whether SARS-CoV-2 in APCs results from virus antigen internalization, or to their permissiveness to SARS-CoV-2 replication, or both. Considering that monocytes, macrophages and dendritic cells are infected by SARS-CoV-2, and that infection of human monocytes triggers inflammasomes,³¹ the infection of such cells in tonsils perhaps enhances inflammation in an already chronically inflamed tissue.^{28, 29}

At present, it is unknown whether SARS-CoV-2 infection of lymphocytes and APCs is detrimental to their function in secondary lymphoid tissues. Moreover, the antigenic specificities of infected lymphocytes in secondary lymphoid organs, and whether some of these cells are naïve, memory, or innate cells, is also presently unknown.

In the present study, SARS-CoV-2 genome was detected by qRT-PCR in nasal washes from 3 of the 12 SARS-CoV-2-positive children, in the absence of COVID-19 symptoms. This agrees with reports that up to 50% of children under 11 years with SARS-CoV-2 infection may be asymptomatic.³⁰ Therefore, the findings suggest that tonsils and olfactory epithelium may be sources of SARS-CoV-2 shedding in nasal washes of asymptomatic children, who may be sources of virus transmission for the community.³¹

Variable loads of SARS-CoV-2 RNA are shed in nasopharyngeal secretions and saliva from COVID-19 patients, including asymptomatic ones.³² In the present cohort, the median viral loads were not significantly different among different sampling sites.

It is noteworthy that two of twelve SARS-CoV-2-positive children had a previous laboratory-confirmed SARS-CoV-2 infection, dating back three and five months prior to tonsillectomy, indicating that they had prolonged or persisting SARS-CoV-2 infection. In further support of SARS-CoV-2 prolonged or persisting infection in tonsils, rather than reinfection, all five children who were seropositive for antibodies to SARS-CoV-2 at the time of tonsillectomy in the present cohort lacked IgM antibodies. However, since we had no access to backup respiratory samples collected at the time of acute infection, it was not possible to ascertain whether the virus detected at the time of tonsillectomy of those two children were of the same strain causing the acute infection, or a reinfecting new one.

Several SARS-CoV-2 proteins alter components of the cell transcriptome, proteome, ubiquitinome, and phosphoproteome, to evade host defenses and be able to persist in low-grade infection profile.³³

Importantly, genome sequencing revealed SARS-CoV-2 of several Pangolin lineages in human tonsils, suggesting that tropism for tonsillar cells is not specific to certain lineages. Whole SARS-CoV-2 genome sequences were not obtained from the infected tissues, which is understandable, considering that the tissue samples may have undergone partial autolysis with viral RNA degradation. In addition, the heterogeneity in the intra-tissular distribution of SARS-CoV-2 RNA among different regions of the tonsils, which were randomly split for the different assays, may have also contributed to that. Nevertheless, the available coverage and sequence depth attained in 10 samples from 8 patients enabled the safe calling of Pangolin lineages.

To the best of our knowledge, this is the first study to identify sites of infection and host cell types of SARS-CoV-2, in tissues where the agent may remain for prolonged times, clinically silent, in the upper respiratory tract of children. In addition to SARS-CoV-2 RNA, viral protein was also detected in tonsils, adenoids, and nasal epithelial cells, an evidence of translational activity in situ. Besides epithelial cells, all major types of lymphomononuclear cells host SARS-CoV-2, which may contribute to the maintenance of SARS-CoV-2 in lymphoid tissues of the upper respiratory tract, with still unknown potential immunoinflammatory consequences. These findings underpin the potential role of hypertrophic tonsils as sites of SARS-CoV-2 infection in children, for an undetermined prolonged time. Such smoldering SARS-CoV-2 infection might involve continuous low-level production of viral proteins and cell-to-

cell transmission, which circumvent immune surveillance and subvert sterilizing immunity by low virus replication and possibly antigenic variation.

TRANSPARENCY DECLARATION

Conflict of interest: The authors declare that they have no conflicts of interest.

Funding: This work was supported by the State of Sao Paulo Research Foundation (FAPESP) [grant numbers 2019/26119-0, 2020/07063-1], the National Research Council (CNPq) [grant number 403201/2020-9], and the Brazilian Coordination for Improvement of Superior Education Personnel (CAPES). EA is the recipient of a longstanding scholarship from CNPq. This study was developed in the framework of Rede Coronaômica MCTI/FINEP, affiliated to RedeVirus/MCTI-Brazil. We would also like to thank the patients and their families for donating the resected tissues and other samples for this study.

Acknowledgments: We are indebted to Prof. José Luiz Proença-Modena (UNICAMP) and Prof. Fabrício Campos (UFRGS) for helpful discussions about the Nanopore sequencing protocol.

Table 1. Sets of primers and probes for the detection of SARS-CoV-2 by RT-PCR.

Gene	Oligonucleotide	Sequence
<i>E</i>	Foward	5'-ACAGGTACGTTAATAGTTAATAGCGT-3'
	Reverse	5'-ATATTGCAGCAGTACGCACACA-3'
	Probe	5'-Fam- ACACTAGCCATCCTTACTGCGCTTCG-BHQ1-3'
<i>N2</i>	Foward	5'-TTA CAA ACA TTG GCC GCA AA-3'
	Reverse	5'-GCG CGA CAT TCC GAA GAA-3'
	Probe	5'-Fam-ACAATTTGCCCCAGCGCTTCAG-BHQ1-3'

Gene	Oligonucleotide	Sequence
E	Foward	5'-ACAGGTACGTTAATAGTTAATAGCGT-3'
	Reverse	5'-ATATTGCAGCAGTACGCACACA-3'
	Probe	5'-Fam- ACACTAGCCATCCTTACTGCGCTTCG-BHQ1-3'
N2	Foward	5'-TTA CAA ACA TTG GCC GCA AA-3'
	Reverse	5'-GCG CGA CAT TCC GAA GAA-3'
	Probe	5'-Fam-ACAATTTGCCCCAGCGCTTCAG-BHQ1-3'
RNAse-P	Foward	5'-AGATTTGGACCTGCGAGCG-3'
	Reverse	5'-GAGCGGCTGTCTCCACAAGT-3'
	Probe	5'-FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ-1-3'

Table 2. Demographic data from the patients enrolled in this study

Characteristics	Number of patients (%)
Sex	
Male	30 (62.5%)
Female	18 (37.5%)
Age	
3 to <6	23 (47.9%)
6 to <9	17 (35.4%)
9 to <12	8 (16.7%)
Surgical indication	
Symptoms suggestive of OSA	27 (56.3%)
Recurrent tonsillitis	8 (16.7%)

Both 13 (27%)

Associated disease	
Allergic rhinitis	19 (39.6%)
Recurrent otitis media	6 (12.5%)
Asthma	4 (8.3%)
None	24 (50%)
Previous diagnosis of COVID-19	2 (4.1%)
Previous contact with infected people	8 (16.7%)

Table 3. Sample types, distribution of Ct values, serological diagnosis and comorbidity information of patientes with positive SARS-CoV-2.

Number	Lymphoid tissue/secretions positive	Ct for Gene E	Ct for Gene N2	Neutralizing antibodies	Serological test (IgG/IgM)	Comorbidities
02	Palatine tonsil	35,0	34,9	None	None	Allergic rhinitis
	Nasal cytobrush	36,0	35			
04	Palatine tonsil	32,6	32,2	None	None	Allergic rhinitis
	Adenoid	31,1	30,7			
	Nasal cytobrush	35,0	34,0	ND	ND	Others infections
	Adenoid	32,7	30,7			
13	Palatine tonsil	34,1	32,3	None	None	Asthma
	Adenoid	32,9	32,7			
18	Palatine tonsil	28,5	25,3	1/4	None	None
	Nasal cytobrush	31,6	25,6			

21	Nasal wash	31,2	29,7	1/32	None	Allergic rhinitis
26	Palatine tonsil	31,2	29,1	None	IgG	None
	Adenoid	28,8	26,5			
28	Nasal wash	31,4	28,7	1/4	None	Serous otitis media
	Palatine tonsil	31,4	28,3			
30	Nasal cytobrush	31,9	27,7	None	IgG	None
	Palatine tonsil	28,4	27,8			
	Adenoid	32,3	31,4			
	Nasal cytobrush	34,2	32,9			
41	Nasal wash	32,6	31,6	1/32	IgG	None
	Palatine tonsil	33,0	31,0			
46	Adenoid	31,0	27,0	1/64	IgG	None
	Adenoid	35,4	33,8			
52	Palatine tonsil	33,0	29,0	1/32	IgG	Allergic rhinitis

ND: Not done

Supplementary table 1. Demographic characteristics and surgery indications for each patient.

Number	Age range	Sex	Reason for surgery	Associated diseases	Previous diagnosis of COVID	Contact with infected people
01	6-10	Male	Recurrent tonsillitis	Recurrent otitis media	No	No
02	0-5	Female	Snore/OSA	Allergic rhinitis	No	No
03	0-5	Female	Snore/OSA	None	No	No
04	6-10	Male	Recurrent tonsillitis and snore/OSA	Allergic rhinitis	No	No
05	6-10	Male	Recurrent tonsillitis and snore/OSA	Allergic rhinitis and recurrent otitis media	No	No
06	0-5	Female	Snore/OSA	Allergic rhinitis and recurrent otitis media	Yes (3 months before surgery) serology	No
07	6-10	Female	Snore/OSA	Allergic rhinitis and asthma	No	No
08	0-5	Male	Snore/OSA	Allergic rhinitis	No	No
9	6-10	Male	Recurrent tonsillitis	None	No	No
10	6-10	Male	Snore/OSA	None	No	No
11	6-10	Female	Recurrent tonsillitis and snore/OSA	None	No	No
12	0-5	Male	Recurrent tonsillitis and snore/OSA	Asthma	No	No
13	0-5	Male	Recurrent tonsillitis and	Allergic rhinitis and GERD	No	No

			snore/OSA			
14	0-5	Female	Recurrent tonsillitis and snore/OSA	None	No	No
15	6-10	Male	Snore/OSA	Allergic rhinitis	No	No
26	0-5	Female	Snore/OSA	Allergic rhinitis	No	No
17	0-5	Female	Recurrent tonsillitis and snore/OSA	Allergic rhinitis	No	No
18	6-10	Male	Snore/OSA	None	No	No
19	0-5	Male	Snore/OSA	Allergic rhinitis and asthma	No	No
20	6-10	Male	Recurrent tonsillitis and snore/OSA	Allergic rhinitis	No	No
21	0-5	Male	Snore/OSA	None	No	No
22	0-5	Male	Snore/OSA	None	No	No
23	6-10	Male	Recurrent tonsillitis and snore/OSA	Recurrent otitis media	No	No
24	6-10	Female	Recurrent tonsillitis and snore/OSA	Allergic rhinitis	No	No
25	6-10	Female	Recurrent tonsillitis	None	Yes (5 months before surgery) PCR	Yes (5 months before surgery) PCR
26	11-15	Female	Snore/OSA	Allergic rhinitis	No	No
27	0-5	Male	Snore/OSA	Allergic rhinitis	No	No
28	0-5	Male	Snore/OSA	None	No	No
29	0-5	Male	Snore/OSA	Allergic rhinitis	No	No

30	0-5	Male	Recurrent tonsillitis	None	No	No
31	0-5	Female	Recurrent tonsillitis	None	No	No
32	0-5	Female	Recurrent tonsillitis and snore/OSA	None	No	Yes (13 months before surgery) PCR
33	6-10	Male	Snore/OSA	Allergic rhinitis and recurrent otitis media	No	No
34	0-5	Male	Snore/OSA	None	No	No
35	6-10	Female	Snore/OSA	Allergic rhinitis	No	No
36	0-5	Female	Snore/OSA	None	No	Yes (1 month before surgery) PCR
37	0-5	Female	Recurrent tonsillitis and snore/OSA	None	No	Yes (1 month before surgery) PCR
38	0-5	Male	Recurrent tonsillitis	Recurrent otitis media	No	No
39	0-5	Male	Recurrent tonsillitis	None	No	No
40	6-10	Male	Recurrent tonsillitis	None	No	No
41	6-10	Male	Recurrent tonsillitis and snore/OSA	None	No	Yes (2 months before surgery) PCR
42	0-5	Male	Snore/OSA	None	No	No
43	0-5	Male	Snore/OSA	None	No	No
44	6-10	Male	Snore/OSA	None	No	Yes (4 months before surgery) PCR
45	6-10	Female	Snore/OSA	Asthma	No	No
46	6-10	Male	Snore/OSA	None	No	Yes (5 months before surgery) PCR

47	6-10	Female	Snore/OSA	Allergic rhinitis	No	Yes (6 months before surgery) PCR
48	6-10	Male	Snore/OSA	None	No	No

Supplementary table 2. Total Assembled genomes of Sars-CoV-2 obtained by Minlon Sequencing with total mutation numbers compared with Reference genome (MN908947.3).

Number	Sample	Reads	Total reads (HAC)	Total Mapped Reads (HAC)	Coverage (100X)	Coverage (>20X)	Sequence Total Length	Mapped Percentage (MN908947.3)	Nucleotide Subs	Aminoacid Subs	GAPS	Clade (nextclade)	Lineage (Pangolin)	BioSample (NCBI)
02	palatine tonsils	173077	180435	19586	16,3	20	5522	10,85	6	4	0	20B	P.2	SAMN30649075
02	nasal cytobrush	179706	211176	101854	67,9	80,7	22256	48,23	18	9	0	20B	P.2	SAMN30649076
04	nasal cytobrush	185466	232057	204188	89,1	95,3	27615	87,99	20	11	0	20B	P.2	SAMN30649077
10	adenoid	8942	7103	2371	4,2	6,8	1740	33,38	1	1	0	20B	B.1.1.33	SAMN30649069
18	palatine tonsils	172135	193224	7879	1,3	2,6	653	4,08	0	0	0	19A	B	SAMN30649072
20	palatine tonsils	40846	13748	19	0	0	-	0,14	-	-	-	failure*	-	-

28	palatine tonsils	230408	246127	91963	20,1	20,4	5220	37,36	1	0	0	19A	B	SAMN30649070
28	nasal cytobrush	167552	84898	5	0	0	0	0,01	-	-	-	failure*	-	-
30	adenoid	92205	108205	21	0	0	-	0,02	-	-	-	failure*	-	-
41	palatine tonsils	67270	80365	55040	30,4	43,3	11215	68,49	20	12	0	20J (Gamma, V3)	P.1	SAMN30649079
41	adenoid	246159	265145	313783	80	88	25580	84,5	33	18	9	20J (Gamma, V3)	P.1	SAMN30649078
46	adenoid	150776	191253	73641	29,1	30,9	7906	38,5	9	8	0	20J (Gamma, V3)	P.1	SAMN30649080
52	palatine tonsils	5492	879	34	0	1,2	346	3,87	2	0	-	20B	N.5	SAMN30649081
C-	NT-RT	2039	-	-	-	-	-	-	-	-	-	-	-	-
C+	Isolate								10	6	0	20B	B.1.1.33	SAMN32003249

REFERENCES

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579(7798):270-273
2. Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features. *The Pediatric infectious disease journal* 2020; 39(6): 469-477
3. Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. *PNAS* 117(40):24620-24626, 2020
4. Proenca-Modena JL, Pereira Valera FC, Jacob MG, et al. High rates of detection of respiratory viruses in tonsillar tissues from children with chronic adenotonsillar disease. *PLoS One* 2012; 7(8): e42136.
5. Mikola E, Palomares O, Turunen R, et al. Rhinovirus species and tonsillar immune responses. *Clinical and translational allergy* 2019; 9(1): 1-9.
6. Faden H, Callanan V, Pizzuto M, et al. The ubiquity of asymptomatic respiratory viral infections in the tonsils and adenoids of children and their impact on airway obstruction. *International Journal of Pediatric Otorhinolaryngology* 2016; 90: 128-132.
7. Primo, OVB, Lourenço EA, Passos, SD. Detection of respiratory viruses in nasopharyngeal swab and adenoid tissue from children submitted to adenoidectomy: pre- and postoperative analysis. *International Archives of Otorhinolaryngology* 2014; 18(2): 150-154.
8. Viana RMM, Souza JP, Jorge DMM, Martins RB, Castro IA, Cardoso RS, Volpini LPB, Luna LKS, Spano LC, Bellei NCJ, Chahud F, Arruda E, Hyppolito MA. Detection of respiratory viruses in primary cholesteatoma tissues. *J Med Virol* 2021, 93(11):6132-6139.
9. Wendel S, Kutner JM, Machado R, et al. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. *Transfusion* 2020; 60(12): 2938-2951.
10. John R Tyson, JR. et. al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv 2020.09.04.283077;doi:<https://doi.org/10.1101/2020.09.04.283077>.
11. Pater AA, Bosmeny MS, White AA, Sylvain RJ, Eddington SB, Parasrampur M, Ovington KN, Metz PE, Yinusa AO, Barkau CL, Chilamkurthy R, Benzinger SW, Hebert MM, Gagnon KT. High throughput nanopore sequencing of SARS-CoV-2 viral genomes from patient samples. *J Biol Methods*. 2021 Sep 27;8(COVID 19 Spec Iss):e155. doi: 10.14440/jbm.2021.360. PMID: 34631911; PMCID: PMC8493558.
12. Heng Li, Minimap2: pairwise alignment for nucleotide sequences, *Bioinformatics*, Volume 34, Issue 18, 15 September 2018, Pages 3094–3100, <https://doi.org/10.1093/bioinformatics/bty191>.

13. Daniel Mapleson, Nizar Drou, David Swarbreck, RAMPART: a workflow management system for de novo genome assembly , *Bioinformatics*, Volume 31, Issue 11, 1 June 2015, Pages 1824–1826, <https://doi.org/10.1093/bioinformatics/btv056>.
14. Aksamentov I, Roemer C, Hodcroft EB, et al. Nextclade: clade assignment, mutation calling and quality control for viral genomes. *Journal of Open Source Software* 2021; 6(67): 3773.
15. O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus evolution* 2021; 7(2): veab064.
16. Voloch CM, da Silva F Jr, de Almeida LG, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *Journal of virology* 2021; 95(10): e00119-21.
17. Sola AM, David AP, Rosbe KW, et al. Prevalence of SARS-CoV-2 infection in children without symptoms of coronavirus disease 2019. *JAMA pediatrics* 2020; 175(2): 198-201.
18. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ* 2020; 370: m3249.
19. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020; 181(7): 1489-1501.
20. Fazolo T, Lima K, Fontoura JC, et al. Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. *Nature Communications* 2021; 12(1): 6844.
21. Pontelli MC, Castro ÍA, Martins RB, et al. SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients. *Journal of Molecular Cell Biology* 2022; 14(4):mjac021.
22. Wang X, Liu Z, Lu L, et al. The putative mechanism of lymphopenia in COVID-19 patients. *Journal of Molecular Cell Biology* 2022; 14(5):mjac034.
23. Xiang Q, Feng Z, Diao B, et al. SARS-CoV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs. *Frontiers in immunology* 2021; 12: 661052.
24. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature* 2022 612:758-763
25. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine* 2020; 26(5): 681-687.
26. Castro IA, Jorge DM, Ferreri LM, et al. Silent infection of B and CD8+ T lymphocytes by influenza A virus in children with tonsillar hypertrophy. *Journal of virology* 2020; 94(9): e01969-19.

27. Vibholm LK,, Nielsen SSF, Pahus MH, Frattari GS, Olesen R, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. *EBioMedicine* 2021; 64:103230.
28. Rodrigues TS, de Sá KS, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *Journal of Experimental Medicine* 2021; 218(3): e20201707.
29. Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2–infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. *The Journal of infectious diseases* 2020; 222(5): 734-745.
30. Dawood FS, Porucznik CA, Veguilla V, et al. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. *JAMA pediatrics* 2022; 176(1): 59-67.
31. Almadhi MA, Abdulrahman A, Sharaf SA, et al. The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. *International journal of infectious diseases* 2021; 105: 656-661.
32. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nature Medicine* 2021; 27(5): 892-903.
33. Desimmie BA, Raru YY, Awadh HM, He P, Teka S, Willenburg KS. Insights into SARS-CoV-2 persistence and its relevance. *Viruses* 2021, 13(1025):1-23.




Figure 1. SARS-CoV-2 viral loads and antigen detection. A) Quantification of SARS CoV-2 RNA genome copies in palatine tonsil and adenoid tissues, nasal washes and nasal cytobrushes from patients with chronic adenotonsillar disease (\pm SD). B). Representative section of an adenoid positive for SARS-CoV-2 NP protein in pseudo-stratified ciliated epithelium, showing SARS-CoV-2-infected cells with red positive signal. C). Representative section of a palatine tonsil positive for SARS-CoV-2 NP protein in a lymphoid follicle. D) Representative section of a palatine tonsil positive for SARS-CoV-2 NP protein in the interfollicular area. Scale bar: 100 μ m






Figure 2. Expression of ACE2 and TMPRSS2 in tonsils. A). Palatine tonsil staining for ACE2, TMPRSS2 and the S protein of SARS-CoV-2. B). Mean fluorescence intensity of ACE2 and TMPRSS2 in SARS-CoV-2-infected tonsils and controls.

A



B




Figure 3. Immune phenotyping of SARS-CoV-2 NP-positive tonsillar cells by flow cytometry. A) A representative gating illustrating the infected population in SARS-CoV-2-negative (Control) and SARS-CoV-2-positive (Patient) tonsils. B) Frequencies of infected immune cells in adenoids and palatine tonsils positive




Figure 4. Immunofluorescence for SARS-CoV-2 in cytobrush preparations. Representative fields of cytobrush preparations from SARS-CoV-2-negative (A-C) and SARS-CoV-2-positive children (D-G), showing positivity for NP protein in some cells. The inset on F is enlarged on G. Scale bar: 25 μ m.







Figure 5. Schematic representation of the evolution of SARS-CoV-2 clades. Each clade is represented by a color circle, and the samples sequenced in the present cohort with the mutational patterns represented by gray rectangles containing the following information, from top to bottom: sample ID, the clade, and the Pangolin lineage assigned by NextClade. The solid rectangles represent SARS-CoV-2 genomes assembled with higher coverage, and the dashed ones represent those with lower coverage, but carrying enough defining mutations to enable lineage assignment. (AD: adenoid; PT: palatine tonsil; NC: nasal cytobrush).



Supplementary Fig. 1. Controls used to standardize immunohistochemistry protocol for SARS-CoV-2 NP protein. A) Non infected Vero CCL-81 cells. B) SARS-CoV-2-infected Vero CCL-81 cells showing abundant reddish signal. C). Representative section of a palatine tonsil negative for SARS-CoV-2, used as negative control, showing absence of signal.